CreativeOne Wealth LLC Grows Stake in Lantheus Holdings, Inc. $LNTH

CreativeOne Wealth LLC increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 124.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,080 shares of the medical equipment provider’s stock after purchasing an additional 8,905 shares during the quarter. CreativeOne Wealth LLC’s holdings in Lantheus were worth $1,569,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in shares of Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in Lantheus by 2.2% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock valued at $155,101,000 after buying an additional 34,052 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Lantheus by 2.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock valued at $134,534,000 after buying an additional 31,454 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its holdings in Lantheus by 39.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider’s stock valued at $87,124,000 after buying an additional 273,838 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,838,066 shares of company stock valued at $384,430,031. Insiders own 1.50% of the company’s stock.

Lantheus Price Performance

NASDAQ:LNTH opened at $55.50 on Friday. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of 14.76 and a beta of 0.14. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The business has a 50 day simple moving average of $69.69 and a 200-day simple moving average of $83.36. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Lantheus’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.80 earnings per share. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the subject of several research analyst reports. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Truist Financial set a $63.00 price target on Lantheus and gave the company a “hold” rating in a report on Monday, August 11th. Finally, B. Riley cut their price target on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a report on Monday, June 23rd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $105.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.